Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $64.43 Average PT from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $66.50.

Several analysts have recently commented on the stock. Jefferies Financial Group lifted their price target on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. HC Wainwright lifted their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Wedbush reissued an “outperform” rating and set a $46.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Finally, Truist Financial upped their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th.

Dianthus Therapeutics Stock Up 9.0%

NASDAQ DNTH opened at $50.75 on Friday. The business’s fifty day simple moving average is $44.41 and its 200-day simple moving average is $36.07. The firm has a market cap of $2.19 billion, a PE ratio of -14.58 and a beta of 1.59. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $57.50.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Research analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This represents a 96.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 216,538 shares of company stock worth $8,283,175. Company insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. PSP Research LLC purchased a new position in Dianthus Therapeutics during the 4th quarter valued at about $524,000. Profund Advisors LLC acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $879,000. UBS Group AG boosted its stake in shares of Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after purchasing an additional 469,547 shares during the period. Vanguard Group Inc. grew its holdings in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $135,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.